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Abstract
Background: Decreased expression of adiponectin (ADIPOQ) is associated with an increased risk for developing
colorectal cancer (CRC) in humans. This study was designed to determine whether polymorphisms present in the
ADIPOQ and its type 1 receptor (ADIPOR1) could affect the risk of CRC.
Methods: We measured five polymorphisms in the ADIPOQ and two polymorphisms in ADIPOR1, and analyzed
their associations with CRC risk in 420 CRC patients and 555 age- and gender-matched healthy individuals.
Results: Multivariate logistic regression analyses revealed that the CRC risks (adjusted odds ratio and 95%
confidence interval) associated with the ADIPOR1 genotypes were 0.53 (95% CI, 0.35-0.81) for rs12733285C/T, 0.59
(95% CI, 0.45-0.78) for rs1342387A/G, and 0.59 (95% CI, 0.39-0.89) for rs1342387A/A, respectively. Furthermore, the
risks were more significant in carriers of the allele A of rs1342387A/G (adjusted OR, 0.59; 95% CI, 0.46-0.77) than
noncarriers (G/G). In a further subgroup analysis, we observed that rs266729G/C was associated with an increased
risk for colon cancer (adjusted OR, 1.50; 95% CI, 1.05-2.14) but not for rectal cancer (adjusted OR, 0.88; 95% CI, 0.63-
1.22), and that carriers of the G allele had an increased risk for developing colon cancer (adjusted OR, 1.45; 95% CI,
1.03-2.05).
Conclusions: We conclude that the rs12733285C/T genotype and the carriage of the A allele of rs1342387 (A/G or
A/A) in ADIPOR1 are the protective factors for CRC, while that rs266729G/C and G allele of ADIPOQ are the risk
factors for colon cancer after excluding rectal cancer cases.
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Background
Colorectal cancer (CRC) is one of the most common
gastrointestinal tumors worldwide[1]. Epidemiological
studies have demonstrated that some risk factors and
interactions between genetic and environmental factors
m a yp l a yi m p o r t a n tr o l e si n the pathogenesis of that
cancer [2,3]. For example, individual genetic susceptibil-
ity is likely to play an important role in the development
of some 35% of the CRC cases [4], suggesting that
genetic background is one of the critical CRC risk fac-
tors [5,6].
Many studies have demonstrated that obesity could
increase the risk of cancer, including CRC [7-9]. In
obese patients, adiponectin, a protein secreted by adi-
pose tissue, has lower expression than that in non-obese
subjects [10,11], implying that decreased expression of
adiponectin (ADIPOQ) may be associated with an
increased risk for developing colorectal cancer (CRC) in
humans [12-15]. Adiponectin and its receptors are
expressed in colonic tissue [16]. For example, the
expression of ADIPOR1 and ADIPOR2 are higher in col-
orectal carcinomas than in normal colonic epithelium
[17]. Adiponectin seems to act in preneoplastic colonic
lesions to regulate cell growth by activating, altering, or
interacting with several pathways including leptin and
NFB pathway [18]. However, the opposite evidence has
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ciated with the risk of CRC [13], and that adiponectin
can suppress the cell proliferation of colon cancer via
AdipoR1- and -R2-mediated AMPK activation[19].
Several polymorphisms of adiponectin have been
shown to affect adiponectin plasma levels[20,21]. Poly-
morphisms of the ligand (ADIPOQ,) and its type 1
receptor (ADIPOR1) are associated with the risk for
insulin resistance, cardiovascular disease, and diabetes
mellitus [20-26]. Polymorphisms of ADIPOR1 have been
associated with the risk for cancers, probably by affect-
ing adiponectin plasma levels [27-30]. Polymorphisms in
the adiponectin gene have also been shown to correlate
with adiponectin plasma levels, The genotypes rs266729
C/C, rs1501299 T/T, and rs2241766 G/G were respec-
tively associated with decreased adiponectin plasma
levels [20,21], suggesting that these polymorphisms may
be associated with increased risk of developing CRC. In
a population-based case-control study, we genotyped
seven polymorphisms of ADIPOQ and ADIPOR1 genes
to confirm such a hypothesis.
Methods
Four hundred and twenty inpatients who had been diag-
nosed histologically as CRC (colon cancer, n = 191, and
rectum cancer, n = 229) in Nanjing First hospital affiliated
to Nanjing Medical University from January 2007 to Janu-
ary 2010 were recruited consecutively for this study. The
case cohort ranged in age from 30 to 93 years (mean ±
SD, 62.9 ± 12.3 years). Five hundred and fifty five age-and
gender-matched healthy individuals who came to hospital
for routine health check were employed as non-cancer
controls whose ages ranged from 44 to 91 years (mean ±
SD, 61.7 ± 10.7 years). Both case and control cohorts were
from the same geographic region of Nanjing City, Jiangsu,
China. For all CRC cases and control individuals, clinical
characteristics of each subject, including smoking [Cumu-
lative cigarette dose (pack-years) was calculated by the fol-
lowing formula: pack-years = (packs per day)×(years
smoked), those who had smoked at least once a day for >1
year in their lifetime were considered smokers, and non-
smokers were defined as ones who had stopped smoking
at least 1 year before diagnosis in the patients and 1 year
before the date signed on an informed consent for blood
sample collection in the case of controls or who had never
smoked in their lifetime.], drinking and related disease his-
tory (such as other cancer, diabetes and so on), was col-
lected via a questionnaire designed in-house by the
Department of Gastroenterology in the hospital. There
was no significant difference in the demographic data
between the two groups. This study protocol was
approved by the Institutional Review Board of the hospital,
and written informed consents were obtained from all
participants.
Genomic DNA was extracted from peripheral blood
mononuclear cells of CRC patients and controls using a
E.Z.N.A.
® S EB l o o dD N AK i t( O m e g aB i o - T e k ,I n c ,
Norcross, GA, UAS) according to the manufacturer’s
instructions. Briefly, cells were lysed by a cell lysis solu-
tion and contaminated RNA in the samples was then
removed by RNase A treatment and the protein was
precipitated by the protein precipitation solution. The
genomic DNA was finally precipitated by isopropanol,
followed by being washed with 70% ethanol.
Polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP) was applied to detect the
polymorphic sites of ADIPOQ and ADIPOR1 as shown
in Table 1. PCR amplification was performed in a 25 μL
reaction system consisting of 0.5 mmol/L of each pri-
mer, 4 mmol/L of MgCl2, 1.25 U of Ampli Taq Poly-
merase, and PCR buffer (10 mmol/L of Tris-HCl, pH
8.3; 50 mmol/L of KCl). After the denaturation at 94°C
5 min, DNA amplification was achieved by 35 cycles of
denaturing at 94°C for 30 sec, annealing at a certain
temperature (as shown in Table 1) for 30 sec, extension
at 72°C for 30 sec, and then followed by 72°C for 7 min.
For restriction enzyme digestion, 10 μLP C Rp r o d u c t
was digested by 10 U of Hin6I (MBI Fermentas, Vilnius,
Lithuania) with buffer Tango for rs266729, Hinf I (MBI)
with buffer B for rs822395, AvaI (MBI) with buffer
Tango for rs2241766, NspI(MBI) with buffer Tango for
rs1501299, and NsiI (MBI) with buffer R for rs12733285
in a final volume of 30 μL and incubated at 37°C(Tru9 I
with buffer R for rs822396 at 65°C) overnight. More-
over, 10U BccI (New England Biolabs, Beverly, MA,
USA) with NEBuffer 1 was utilized for digesting the 10
μL PCR product of rs1342387 in a final volume of 30
μL and incubated at 37°C overnight. Deoxyribonucleic
acid fragments of rs266729, rs1342387 and rs822396
were separated by 3% agarose gel electrophoresis, and
4% agarose gel was used for the fragment of rs822395,
rs2241766, rs2232853 and rs12733285. To validate the
genotyping results, the genotyping experiments were
repeated, a random selection of 10% of all samples was
genotyped twice by direct sequence for quality control.
Statistical analysis of genotype distribution and allele
frequencies was performed by using the c2t e s tw i t h
SPSS 11.0 for Windows (SPSS, Chicago, IL). Odds ratios
(OR) and 95% confidence intervals (CIs) were calculated
using a logistic regression model. Differences in mean
values were evaluated using t-test. The P value < 0.05
was considered statistically significant.
Results and Discussion
Four hundred twenty patients with colorectal cancer and
five hundred fifty and five healthy controls were evalu-
ated in this population-based case-control association
study, and there were no statistically significant
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acteristics as summarized in Table 2.
The genotype distribution of the polymorphisms of
ADIPOQ and ADIPOR1 between the cases and controls
are presented in Table 3. The observed frequencies of
all tested genotypes and alleles in controls did not
derivate from the Hardy-Weinberg equilibrium. Logistic
regression analysis revealed a significantly decreased risk
(adjusted OR, 0.53; 95% CI: 0.35-0.81) for the
rs12733285 C/T heterozygote when compared with the
rs12733285 C/C wild-type homozygote as shown in
Table 3. Similarly, carriers of the A allele (rs1342387 A/
G or A/A) had decreased risk (adjusted OR 0.59; 95%
CI: 0.45-0.78, and adjusted OR 0.59; 95% CI: 0.39-0.89,
respectively) for CRC compared with noncarriers (i.e.,
rs1342387 G/G) as shown in Table 3, suggesting that
carriers of the rs1342387 A allele had a significantly
decreased risk for colorectal cancer (adjusted OR 0.59;
95% CI: 0.46-0.77). In contrast, the distribution of the
five polymorphisms (rs266729, rs822395, rs822396,
rs1501766 and rs1501299) in ADIPOQ was not statisti-
cally significantly different between the case and control
groups as shown in Table 3.
Subgroup analysis was performed based on the tumor
site in this study, and logistic regression analysis
revealed a significantly increased risk for the rs266729G/
C heterozygote (adjusted OR, 1.50; 95% CI: 1.05-2.14) as
compared with the rs266729 C/C wild-type homozygote
as shown in Table 4, suggesting that carriers of the
266729 G allele had a significantly increased risk for col-
orectal cancer (adjusted OR 1.45; 95% CI: 1.03-2.05).
However, there was no difference in the genotype distri-
bution between the sub-cohort of colon cancer and rec-
tal cancer.
Through the population-based case-control study of
420 CRC patients and 555 age-and gender- matched
Table 1 Primers and PCR conditions for genotype detection of ADIPOQ and ADIPOR1
SNP Gene Position Annual
temperature
Primer sequence Restriction
enzyme
PCR-RFLP
products(bp)
Genotype
(5’-3’)
rs266729 ADIPOQ 5′ flanking -11365
C®G
63°C GATGTCTTGTTGAAGTTGGTGCTG
TAGAAAGTTTAGGCTTGAAGTGGC
Hin6 I 176
176, 100, 76
100, 76
CC
GC
GG
rs822395 ADIPOQ Intron 1 -4034
A®C
50°C TGATCGCACCTATTAGTGGAGgAAT*
TCCAGAATATGTGAAAGCCCCAGAG
Hinf I 208
208, 187, 21
187, 21
AA
AC
CC
rs822396 ADIPOQ Intron 1 -3964
A®G
58°C ATCAGAGTCCGTTCTTGGT
ACTGCTTGTCACCTCCACC
Tru9 I 458
458,259,199
259,199
GG
GA
AA
rs2241766 ADIPOQ Exon 2 +45 T®G 51°C GATCAAGGTGGGCTGCAATA
AGTCGTGGTTTCCTGGTCAT
Ava I 246
246,220,26
220,26
TT
TG
GG
rs1501299 ADIPOQ Intron 2 +276
G®T
50°C TCTAGGCCTTAGTTAATAATGcA*
CAGGAAACCACGACTCAAG
Nsp I 250
250,230,20
230,20
AA
AC
CC
rs12733285 ADIPOR1 Intron 1 -1742
C®T
66°C GTCATGCTATGCTCAACCCACAtGC*
CTTCCAGCTTCCTGTTCTCCTTAG
Nsi I 209
209,183,26
183,26
CC
CT
TT
rs1342387 ADIPOR1 Intron 4 +5843
G®A
60°C CACCTGGTAGTGGGATTGG
GAGAAGCTGAGGCAGAGCA
Bcc I 474
474,294,180
294,180
GG
AG
AA
* Primers in lower case letters denote the mismatched position that is required for subsequent restriction digestion for the differentiation of the polymorphisms.
Table 2 Demographic and clinical characteristics of CRC
patients and the controls
Variables Patients, n (%) Controls, n (%) P-
value
Total cases 420 555
Gender
Male 280 (66.67) 339 (61.08) 0.084
Female 140(33.33) 216 (38.92)
Age
Mean ± SD 62.88 ± 12.32 61.71 ± 10.65 0.113
≤ 60 186(44.29) 271 (48.83) 0.082
>60 234(55.71) 284 (51.17)
Smoking status (Pack-year)
Non-smoker 316 (73.24) 406 (73.15) 0.508
Smoker 104(24.76) 149(26.85)
Alcohol consumption
(year)
Never 274(65.24) 379 (68.29) 0.514
≤ 15 119 (28.33) 139(25.05)
> 15 27 (6.43) 37 (6.67)
Tumor site
Colon 191(45.48) ––
Rectal 229(54.52) –
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that CRC patients had lower frequency of rs2733285C/T
and rs1342387A/G or A/A than healthy controls, and
that carriers of the rs2733285T and rs1342387A allele
had a significantly decreased risk for developing CRC.
Moreover, we also revealed that rs266729G/C genotype
and rs266729G allele was a risk factor for colon cancer.
It has been well known that obesity is one of the
major risks for CRC [31,32] and that lack of physical
exercise, diets with high sugar, refined grains, and low
fiber are all believed as the risks of CRC [33-36]. Adipo-
nectin is secreted by adipose tissue, and epidemic
studies have demonstrated that its plasma levels were
inversely correlated to BMI [37,38]. Recent studies have
shown that polymorphism in ADIPOQ (rs2241766) is
associated with the risk of breast cancer [27], and that a
polymorphism rs266729 is associated with the risk of
colorectal cancer [28]. However, in this case-control
study, we failed to replicate the association between the
two positive variants at ADIPOQ (rs2241766, and
rs266729) and CRC risk in Chinese population. Our
findings are consistent with the studies reported in
Czech [30] and British populations[39]. However, our
subgroup analysis still revealed that rs266729 G/C and
Table 3 The genotype distribution of ADIPOQ and ADIPOR1 in CRC patients and controls
Genotypes Patients, n (%) Controls, n (%) OR (95% CI)
a OR (95% CI)
b P value
c
rs266729
CC 173(41.79) 243 (43.78) Reference Reference 0.705
GC 205 (48.81) 261(47.03) 1.10(0.84,1.44) 1.12(0.85,1.46)
GG 42(10.00) 51(9.19) 1.16(0.74,1.82) 1.18(0.75,1.86)
GC/GG 247(58.81) 312(56.22) 1.12(0.86,1.44) 1.13(0.87,1.46)
rs822395
AA 343(81.67) 440(79.28) Reference Reference 0.38
AC 70(16.67) 109(19.64) 0.82(0.59,1.15) 0.81(0.58,1.12)
CC 7(1.67) 6(1.08) 1.50(0.50,4.49) 1.47(0.49,4.46)
AC/CC 77(18.33) 115(20.72) 0.86(0.62,1.18) 0.84(0.61,1.16)
rs822396
AA 344(81.90) 450(81.08) Reference Reference 0.82
AG 73(17.38) 99(17.84) 0.97(0.69,1.35) 0.99(0.70,1.38)
GG 3(0.71) 6(1.08) 0.65(0.16,2.63) 0.63(0.16,2.54)
AG/GG 76(18.10) 105(18.92) 0.94(0.68,1.31) 0.96(0.69,1.34)
rs2241766
TT 190(45.24) 278(50.09) Reference Reference 0.265
TG 193(45.95) 238(42.88) 1.19(0.91,1.55) 1.18(0.91,1.54)
GG 37(8.81) 39(7.03) 1.39(0.85,2.26) 1.42(0.86,2.32)
TG/GG 230(54.76) 277(49.91) 1.22(0.94,1.57) 1.21(0.94,1.57)
rs1501299
CC 220(52.38) 265(47.75) Reference Reference 0.276
AC 160(38.10) 224(40.36) 0.86(0.66,1.13) 0.87(0.66,1.15)
AA 40(9.52) 66(11.89) 0.73(0.47,1.12) 0.95(0.67,1.36)
AC/AA 200(47.62) 290(52.25) 0.83(0.65,1.07) 0.84(0.65,1.09)
rs12733285
CC 386(91.90) 477(85.95) Reference Reference 0.004
CT 34(8.10) 78(14.05) 0.54(0.35,0.82) 0.53(0.35,0.81)
TT 0(0.00) 0(0.00) ––
CT/TT 34(8.10) 78(14.05) 0.54(0.35,0.82) 0.53(0.35,0.81)
rs1342387
GG 213(50.71) 210(37.84) Reference Reference 0
AG 157(37.38) 263(47.39) 0.59(0.44,0.78) 0.59(0.45,0.78)
AA 50(11.90) 82(14.77) 0.60(0.40,0.90) 0.59(0.39,0.89)
AG/AA 207(49.29) 345(62.16) 0.59(0.46,0.77) 0.59(0.46,0.77)
aCrude odds ratio
bAge and gender adjusted odds ratio
cc
2 test for all genotypes between the two groups
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not for rectal cancer. These findings may partly explain
the previous contradictive studies on the association
between the polymorphism of rs2241766 and CRC risk
[28]. Moreover, basic research had also predicted that
ADIPOQ and ADIPOR have more potential effects on
colon cancer than on rectal cancer [40], indicating that
rs266729 G/C and 266729 G allele were risk factors for
colon cancer but not for rectal cancer, several studies
have confirmed that polymorphisms rs266729 C/C,
rs1501299 T/T and rs2241766 G/G in the ADIPOQ
were associated with adiponectin plasma levels
[20,21,24]. In particularly, such association were also
deduced in Chinese population that G allele of rs266729
was significantly associated with lower adiponectin
plasma levels[41], and that low levels of adiponectin was
associated with the increased risk of CRC [13,42].
The association between adiponectin type 1 receptor
level and the two polymorphisms (rs12733285,
rs1342387) in ADIPOR was still unclear. In this case-
control study, the association between polymorphisms
in ADIPOR1 (rs12733285, rs1342387) and CRC risk has
also been investigated, and the results indicate that indi-
viduals with rs12733285C/T or rs1342387A/G or A/A
had a decreased risk of CRC, which was similar with the
finding in North American populations [28]. However,
Table 4 Genotype distribution in relation to sub sites in colorectal cancer
Genotypes controls Colon cancer Rectal cancer
n (%) n (%) OR(95% CI)
a n(%) OR (95% CI)
a
rs266729
CC 243(43.78) 68(35.60) Reference 105(45.85) Reference
GC 261(47.03) 107(56.02) 1.50(1.05,2.14) 98(42.79) 0.88(0.63,1.22)
GG 51(9.19) 16(8.38) 1.19(0.64,2.25) 26(11.35) 1.20(0.71,2.04)
GC/GG 312(56.22) 123(64.40) 1.45(1.03, 2.05) 124(54.15) 0.94(0.69,1.28)
rs822395
AA 440(79.28) 155(81.15) Reference 188(82.10) Reference
AC 109(19.64) 32(16.75) 0.82(0.53,1.27) 38(16.59) 0.80(0.53,1.20)
CC 6(1.08) 4(2.09) 1.63(0.45,5.97) 3(1.31) 1.25(0.31,5.06)
AC/CC 115(20.72) 36(18.85) 0.86(0.56,1.31) 41(17.90) 0.82(0.55,1.22)
rs822396
AA 450(81.08) 161(84.29) Reference 183(79.91) Reference
AG 99(17.84) 28(14.66) 0.830(0.52,1.31) 45(19.65) 1.11(0.75,1.65)
GG 6(1.08) 2(1.05) 0.93(0.18,4.70) 1(0.44) 0.38(0.05,3.17)
AG/GG 105(18.92) 30(15.71) 0.83(0.53,1.30) 46(20.09) 1.07(0.72,1.58)
rs2241766
TT 278(50.09) 91(47.64) Reference 99(42.23) Reference
TG 238(42.88) 87(45.55) 1.10(0.78,1.56) 106(46.29) 1.25(0.90,1.72)
GG 39(7.03) 13(6.81) 1.07(0.54,2.11) 24(10.48) 1.71(0.97,3.01)
TG/GG 277(49.91) 100(52.36) 1.10(0.79,1.53) 130(56.77) 1.31(0.96.1.79)
rs1501299
CC 265(47.75) 97(50.79) Reference 123(53.71) Reference
AC 224(40.36) 72(37.70) 0.86(0.60,1.24) 88(38.43) 0.88(0.63,1.22)
AA 66(11.89) 22(11.52) 0.93(0.54,1.60) 18(7.86) 0.59(0.34,1.04)
AC/AA 290(52.25) 94(49.21) 0.89(0.64,1.24) 106(46.29) 0.81(0.59,1.11)
rs12733285
CC 477(85.95) 175(91.62) Reference 211(92.14) Reference
CT 78(14.05) 16(8.38) 0.51(0.29,0.91) 18(7.86) 0.51(0.30,0.88)
TT 0(0.00) 0(0.00) – 0(0.00) –
CT/TT 78(14.05) 16(8.38) 0.51(0.29,0.91) 18(7.86) 0.51(0.30,0.88)
rs1342387
GG 210(37.84) 99(51.83) Reference 114(49.78) Reference
AG 263(47.39) 69(36.13) 0.57(0.40,0.81) 88(38.43) 0.62(0.45,0.87)
AA 82(14.77) 23(12.04) 0.54(0.32,0.93) 27(11.79) 0.66(0.40,1.09)
AG/AA 345(62.16) 92(48.17) 0.57(0.41,0.79) 115(50.22) 0.62(0.46,0.85)
aAge and gender adjusted odds ratio
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in case and control groups, in a sharp contrast with 15%
of the rs12733285T/T genotype in North American
population [27,28]. Nevertheless, our results are consis-
tent with Hap-Map data among western Asian popula-
tion http://www.hapmap.org/index.html.en. For
polymorphism (rs1342387) of ADIPOR1, the distribution
of genotypes in our studies was similar to the results by
Wang et al [43]. Previous clinical studies have shown
that the genotypes rs1342387A/G or A/A were asso-
ciated with higher adiponectin plasma levels [21], and
G/G genotype of rs1342387 of the ADIPOR1 gene was
also associated with the indicators of obesity [44,45].
Therefore, the reason of the G/G genotype of rs1342387
as a risk factor for CRC may be correlated to obesity
and insulin resistance. In addition, clinical studies have
also revealed that adiponectin type 1 receptor is related
to colorectal cancer progression[46]. However, the func-
tion of rs1342387 in ADIPOR1 remains unclear, and the
direct relationship between rs1342387 and the risk of
CRC needs to be further evaluated.
Conclusions
This case-control study demonstrates that polymorph-
isms in ADIPOR1 (rs12733285, rs1342387) are asso-
ciated with the decreased risk of CRC, and
polymorphism in ADIPOQ (rs266729) is a risk for colon
cancer but not for rectal cancer.
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ADIPOQ: adiponectin; CRC: colorectal cancer; ADIPOR1: adiponectin type 1
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